Your session is about to expire
← Back to Search
Host Dendritic Cell Therapy for Lymphoma
Study Summary
This trial is testing whether a specific type of cell therapy can help people with cancer after a stem cell transplant, and whether it is safe and feasible.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am capable of limited self-care.Women who could become pregnant must have a negative pregnancy test before joining the study.I have had a stem cell transplant from a donor.I haven't had any cancer except skin cancer or cervical pre-cancer in the last 5 years.I do not have any illnesses that would shorten my life to less than 6 months, aside from my current condition.I have a history of autoimmune diseases like lupus, rheumatoid arthritis, or thyroiditis.I do not have any active infections, including fungal or hepatitis.My skin condition after a transplant is worse than mild.My kidneys are working well.I haven't received chemotherapy in the last 4 weeks.My lung function is more than half of what is considered normal.My liver is functioning within the required limits.I am using effective birth control methods or abstaining.I have received a donor lymphocyte infusion before.You are expected to live for more than 6 months.I am between 18 and 70 years old.I have a specific type of blood cancer and am eligible for a stem cell transplant.I am HIV positive.I am using effective birth control methods during the study.My heart pumps well, with an ejection fraction over 50%.
- Group 1: Group 1
- Group 2: Group 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals aged 60 or older eligible to join this experiment?
"To be accepted into this medical study, patients must fall within the 18 to 70 years old age range. 339 trials are available for those aged under 18 while 2402 studies have been designed with seniors in mind."
Is this experiment accepting participants at present?
"Clinicaltrials.gov states that this medical trial is not currently open for recruitment, despite having been originally posted on August 1st 2009 and last updated on October 28th 2010. However, there are still 2570 other trials actively searching for participants."
Has the FDA sanctioned MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) for therapeutic use?
"The safety of the MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) is appraised to be a 1, as it is currently in Phase 1 trials where efficacy and safety data are both scarce."
Under what conditions is one eligible to participate in this trial?
"To be eligible to participate in this trial, participants must have a diagnosis of multiple myeloma and should lie within the age range of 18-70. Approximately 25 subjects are required for successful completion of the study."
Share this study with friends
Copy Link
Messenger